Cells with double positivity (α-SMA+ CD163+) ranged from 10.2% to 13.6% of all α-SMA+ cells in these cancer types, which is consistent with our pan-cancer single-cell analysis and a previous report in pancreatic cancer55. Here, CD163 is linked to cancer.